Emerging infectious disease agents and their potential threat to transfusion safety:

Transfusion

Volumn 49, Issue SUPPL. 2, 2009, Pages

  Stramer, Susan L ^a   Hollinger, F Blaine ^b   Katz, Louis M ^b   Kleinman, Steven ^b   Metzel, Peyton S ^b   Gregory, Kay R ^b   Dodd, Roger Y ^b  

^a Scientific Support Office   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASMA PHAGOCYTOPHILUM; ANTHRAX; ARTICLE; BABESIA; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BLOOD DONOR; BLOOD TRANSFUSION; BOTULISM; CANADA; CHIKUNGUNYA ALPHAVIRUS; CHRONIC WASTING DISEASE AGENT; CLOSTRIDIUM BOTULINUM; DENGUE VIRUS; DISEASE TRANSMISSION; FRANCISELLA TULARENSIS; HEPATITIS A VIRUS; HEPATITIS E VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION; INFECTION RISK; INFLUENZA VIRUS A H5N1; LEISHMANIA; NONHUMAN; PARVOVIRUS; PLAGUE; PLASMODIUM; RECIPIENT; RISK REDUCTION; SAFETY; SMALLPOX; ST LOUIS FLAVIVIRUS; THREAT; TRYPANOSOMA CRUZI; TULAREMIA; UNITED STATES; VARIANT CREUTZFELDT JAKOB DISEASE; VIRUS HEMORRHAGIC FEVER; YERSINIA PESTIS;

BLOOD TRANSFUSION; COMMUNICABLE DISEASES, EMERGING; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; RISK FACTORS; SAFETY;

EID: 68149125565     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02279.x     Document Type: Article

References (115)

1. Emerging Infections. Microbial threats to health in the United States. Washington, DC : Institute of Medicine 1992.
2. Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 2007 447 : 279 83.
3. Morens DM, Folkers GK, Fauci AS. Emerging infections: a perpetual challenge. Lancet Infect Dis 2008 8 : 710 19.
4. Parrish CR, Holmes EC, Morens DM, Park EC, Burke DS, Calisher CH, Laughlin CA, Saif LJ, Daszak P. Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev 2008 72 : 457 70.
5. Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004 10 (12 Suppl S88 S97.
6. Petersen LR, Hayes EB. Westward ho? - the spread of West Nile virus. N Engl J Med 2004 351 : 2257 9.
7. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003 349 : 1205 6.
8. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007 14 : 671 6.
9. Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Annu Rev Med 2004 55 : 191 207.
10. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007 44 : 32 41.
11. Leiby DA. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 2004 87 (Suppl 2 S120 2.
12. Leiby DA. Emerging infectious agents. Dev Biol (Basel) 2005 120 : 11 5.
13. Kleinman S. Hepatitis G virus biology, epidemiology, and clinical manifestations: implications for blood safety. Transfus Med Rev 2001 15 : 201 12.
14. Hino S, Miyata H. Torque teno virus (TTV): current status. Rev Med Virol 2007 17 : 45 57.
15. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008 112 : 2617 26.
16. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003 43 : 1007 17.
17. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003 349 : 1236 45.
18. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006 91 : 221 30.
19. Lefrère JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2008 49 : 797 812.
20. Reesink HW, Engelfriet CP, Hyland CA, Coghlan P, Tait B, Wsolak M, Keller AJ, Henn G, Mayr WR, Thomas I, Osselaer JC, Lambermont M, Beaten M, Wendel S, Qiu Y, Georgsen J, Krusius T, Mäki T, Andreu G, Morel P, Lefrère J-J, Rebulla P, Giovanelli S, Butti B, Busch MP et al. Biobanks of blood from donors and recipients of blood products. Vox Sang 2008 94 : 242 60.
21. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005 353 : 460 7.
22. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005 353 : 451 9.
23. Leiby DA, Herron RM Jr., Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002 42 : 549 55.
24. Leiby DA, Herron RM, Garratty G, Herwaldt BL. Trypanosoma cruzi parasitemia in US blood donors with serologic evidence of infection. J Infect Dis 2008 198 : 609 13.
25. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion 1991 31 : 4 11.
26. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006 46 : 272 7.
27. Wilson K, Ricketts MN. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004 44 : 1475 8.
28. Wilson K, Wilson M, Hébert PC, Graham I. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy. Transfus Med Rev 2003 17 : 89 94.
29. Heneine W, Kuehnert MJ. Preserving blood safety against emerging retroviruses. Transfusion 2006 46 : 1276 8.
30. Foster KR, Vecchia P, Repacholi MH. Risk management. Science and the precautionary principle. Science 2000 288 : 979 81.
31. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky WH, Orciari L, Sanchez EQ, Likos A, Klintmalm GB, Cardo D, LeDuc J, Chamberland ME, Jernigan DB, Zaki SR Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005 352 : 1103 11.
32. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer JA, Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A Jr., Davis JP, Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, Jernigan DB, Rollin PE, Packard MM, Zaki SR, et al. LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006 354 : 2235 49.
33. McQuiston JH, Childs JE, Chamberland ME, Tabor E Working Group on Transfusion Transmission of Tick-borne Diseases. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000 40 : 274 84.
34. Will RG, Ward HJT. Clinical features of variant Creutzfeldt-Jakob disease. Curr Top Microbiol Immunol 2004 284 : 121 32.
35. Tambyah PA, Koay ESC, Poon MLM, Lin RVTP, Ong BKC, Transfusion- Transmitted Dengue Infection Study Group. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008 359 : 1526 7.
36. Chuang VWM, Wong TY, Leung YH, Ma ESK, Law YL, Tsang OTY, Chan KM, Tsang IHL, Que TL, Yung RWH, Liu SH. Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008 14 : 170 7.
37. Mohammed H, Linnen JM, Muñoz-Jordán JL, Tomashek K, Foster G, Broulik AS, Petersen L, Stramer SL. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008 48 : 1348 54.
38. Linnen JM, Vinelli E, Sabino EC, Tobler LH, Hyland C, Lee TH, Kolk DP, Broulik AS, Collins CS, Lanciotti RS, Busch MP. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008 48 : 1355 62.
39. Centers for Disease Control and Prevention (CDC). Dengue hemorrhagic fever - U.S.-Mexico border, 2005. MMWR Morb Mortal Wkly Rep 2007 56 (31 785 9.
40. Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009 48 : 25 30.
41. Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006 90 : 157 65.
42. Charrel RM, de Lamballerie X, Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007 356 : 769 71.
43. Bianco C. Dengue and Chikungunya viruses in blood donations: risks to the blood supply? Transfusion 2008 48 : 1279 81.
44. Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De Valk H, Desenclos JC. Workgroup "Quantitative estimation of the risk of blood donation contamination by infectious agents." Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008 48 : 1333 41.
45. Cardo LJ. Leishmania: risk to the blood supply. Transfusion 2006 46 : 1641 5.
46. Belay ED, Schonberger LB. The public health impact of prion diseases. Annu Rev Public Health 2005 26 : 191 212.
47. Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, Schonberger LB. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis 2004 10 : 977 84.
48. Safar JG, Lessard P, Tamgüney G, Freyman Y, Deering C, Letessier F, DeArmond SJ, Prusiner SB. Transmission and detection of prions in feces. J Infect Dis 2008 198 : 81 9.
49. Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, Banage F, Nzaro E, Kataaha P, Dondero TJ, Pellett PE, Lackritz EM. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006 355 : 1331 8.
50. Dollard SC, Nelson KE, Ness PM, Stambolis V, Kuehnert MJ, Pellett PE, Cannon MJ. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. Transfusion 2005 45 : 500 3.
51. Zou S. Potential impact of pandemic influenza on blood safety and availability. Transfus Med Rev 2006 20 : 181 9.
52. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, Sato S, Kato T, Nishimori H, Tsuji K, Maguchi H, Yoshida JI, Maekubo H, Mishiro S, Ikeda H. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008 48 : 1368 75.
53. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo C-G. Transfusion-transmitted hepatitis E in a "nonhyperendemic" country. Transfus Med 2006 16 : 79 83.
54. Eastlund T, Persing D, Mathiesen D, Kim D, Bleging J, McCann P, Heiler G, Raynovic S. Human granulocytic ehrlichiosis after red cell transfusion. (Abstract). Transfusion 1999 39 (Suppl 117S.
55. Centers for Disease Control and Prevention (CDC). Anaplasma phagocytophilum transmitted through blood transfusion - Minnesota, 2007. MMWR Morb Mortal Wkly Rep 2008 57 (42 1145 8.
56. Slovic P. Perception of risk. Science 1987 236 : 280 5.
57. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K Working Group on Civilian Biodefense. Anthrax as a biological weapon: medical and public health management. JAMA 1999 281 : 1735 45.
58. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001 285 : 1059 70.
59. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. JAMA 2000 283 : 2281 90.
60. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K Working Group on Civilian Biodefense. Smallpox as a biological weapon: medical and public health management. JAMA 1999 281 : 2127 37.
61. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. JAMA 2001 285 : 2763 73.
62. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr., Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Tonat K et al. Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002 287 : 2391 405.
63. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 45 : 580 90.
64. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
65. Mohr H, Ute G, Bayer A, Müller TH. Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009 doi: 10.1111/j.1537-2995.2009.02228.x
66. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
67. Gallian P, Vignolo C, Dombey AM, Mayaudon V, Lin L, Galichet V, Cantaloube JF, De Micco P. Inactivation of a European strain of West Nile virus in single-donor platelet concentrate using the INTERCEPT Blood System. Vox Sang 2006 91 : 345 7.
68. Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW Jr., Stassinopoulos A. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007 47 : 1062 70.
69. Dupuis K, Sawyer L. Inactivation of influenza virus type A H5N1 in platelets and plasma by treatment with the INTERCEPT Blood System. Vox Sang 2008 95 (Suppl 1 301.
70. Pinna D, Sampson-Johannes A, Clementi M, Poli G, Rossini S, Lin L, Vicenzi E. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005 15 : 269 76.
71. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004 44 : 1496 504.
72. Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008 48 : 1676 84.
73. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCI) and long-wavelength UV. Antimicrob Agents Chemother 2003 47 : 475 9.
74. Castro E, Gironés N, Bueno JL, Carrión J, Lin L, Fresno M. The efficacy of photochemical treatment with amotosalen HCI and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007 47 : 434 41.
75. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007 37 : 131 7.
76. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005 45 : 1459 63.
77. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006 90 : 85 91.
78. Rentas F, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007 47 : 240 7.
79. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006 16 : 266 75.
80. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma - a very robust method of virus inactivation. Validated virus safety of Octaplas®. Vox Sang 1998 74 Suppl 1 : 207 12.
81. Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri(n-butyl) phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990 30 : 591 8.
82. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. Virus inactivation by Solvent/Detergent treatment and the manufacture of SD-plasma. Vox Sang 1998 74 Suppl 1 : 203 6.
83. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006 46 : 1168 77.
84. Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008 38 : 271 80.
85. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 9.
86. Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991 60 : 207 13.
87. Gironés N, Bueno JL, Carrión J, Fresno M, Castro E. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006 91 : 285 91.
88. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCI (S-59) and ultraviolet A light. Transfusion 2004 44 : 1732 40.
89. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG. Platelets photochemically treated with amotosalen HCI and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006 46 : 731 40.
90. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003 101 : 2426 33.
91. Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, Sørensen H, Borregaard N, Flament J. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006 46 : 424 33.
92. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F IV., Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004 104 : 1534 41.
93. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005 45 : 1864 75.
94. Corash L, Eiden J, Lin JS. Serious pulmonary adverse events and acute lung injury following repeat platelet transfusions. Transfusion 2008 48 (Suppl 28A.
95. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005 45 : 1331 41.
96. Goodrich R, Roberts T, Folléa G. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. (Abstract). Transfusion 2008 48 (2 Suppl 20A.
97. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 48 : 1061 71.
98. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008 94 : 315 23.
99. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009 49 : 1412 22.
100. Cazenave JP, Waller C, Mendel I, Kientz D, Kandel G, Raidot JP, Wiesel ML, Laforet M, Isola H. Clinical experience with conventional versus INTERCEPT platelet concentrates transfused to all patients during two one-year periods: reduction of adverse events with equivalent use of blood products. Vox Sang 2008 95 (Suppl 1 305 6.
101. Schlenke P, Hagenah W, Andresen S, Bauhaus M, Sundin D, Lin L, Corash L, Wagner T, Kirchner H. Platelet components treated with pathogen inactivation using the INTERCEPT Blood System™: clinical outcomes of the first single-centre clinical trial in Germany. Vox Sang 2007 93 (Suppl 1 171.
102. Infanti L, Job S, Santoro M, Silzle T, Reusch M, Stebler C, Halter J, Sundin D, Propst M, Gratwohl A. Platelet components treated with pathogen inactivation using the INTERCEPT Blood System™: clinical outcomes of the first single-centre observational trial in Switzerland. Vox Sang 2008 95 (Suppl 1 289.
103. Van Haute I, Benoit Y, Bordon V, De Moerloose B, Vandecruys E, Van Lancker S, Van Vooren M, Vandekerckhove B. Therapeutic efficacy and safety of transfusion of pathogen-inactivated platelets to pediatric patients. Vox Sang 2006 91 : 177.
104. Hambleton J, Wages D, Radu-Radulescu L, Adams M, Mackenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002 42 : 1302 7.
105. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L. Fresh frozen plasma prepared with amotosalen HC1 (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation deficiencies. Transfusion 2005 45 : 1362 72.
106. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006 107 : 3753 60.
107. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006 46 : 1693 704.
108. Cazenave JP, Osselaer JC, Waller C, Jacquet M, Lin L, Corash L, Sundin D. An active hemovigilance program utilizing an EDC system to assess safety of 2994 plasma transfusions prepared with the INTERCEPT Blood System™. Transfusion 2008 48 (Suppl 1 29A.
109. Politis C, Kavallierou L, Hantziara S, Katsea P, Triantaphylou V, Richardson C, Tsoutsos D, Anagnostopoulos N, Gorgolidis G, Ziroyannis P. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007 92 : 319 26.
110. Larrea L, Calabuig M, Soler MA, Solves P, Mirabet V, Roig R. Our nine years experience in plasma inactivation. Vox Sang 2007 93 (Suppl 1 167.
111. Castrillo A, Eiras A, Cid J, Castro A, Adelantado M, Abalo M, Areal C, Flores J, Cabrera J. Quality of methylene blue plasma over the last five years. Vox Sang 2006 91 : 182.
112. de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001 114 : 721 23.
113. Alvarez-Larrán A, Del Río J, Ramírez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre J-L, Sanz C, Pereira A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004 86 : 246 51.
114. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004 14 : 39 44.
115. del Río-Garma J, Pereira A, Arroyo JL, Mateo J, Alvarez-Larrán A, Martínez C, Muncunill J, Barbolla L Spanish Group of Apheresis (Grupo Español de Aféresis GEA). ADAMTS-13 activity and von Willebrand factor levels in methylene blue photo-inactivated plasma and processed by either the Springe method or an "in house" system. Vox Sang 2008 95 : 101 5.